D Pharm (Israel) Management Performance Evaluation

DPRM -- Israel Stock  

ILS 430.00  0.60  0.14%

Analysis of D Pharm manpower and management performance can provide insight into D Pharm stock performance. Also an employee sentiment is becoming a valuable factor that investors can use to determine the amount of risk that may be associated with D Pharm LTD future performance. Additionally see Investing Opportunities.

D Pharm Management Effectiveness

The company has return on total asset (ROA) of (42.09) % which means that it has lost $42.09 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (400.0) % meaning that it generated substantial loss on money invested by shareholders.

D Pharm Workforce Comparison

D Pharm LTD is rated below average in number of employees category among related companies. The total workforce of Biotechnology industry is currently estimated at about 1,251. D Pharm maintains roughly 11.0 in number of employees contributing less than 1% to stocks in Biotechnology industry.

D Pharm Profit Margins

The company has Profit Margin (PM) of (112.59) % which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (100.69) % which suggests for every $100 dollars of sales it generated a net operating loss of -1.01.

D Pharm Stakeholders

Golan Bitton CEO, Director
Alexander Kozak Co-Founder, CEO and Pres
David Grossman Chairman of the Board
Itschak Shrem Chairman of the Board
Aharon Schwartz Executive Chairman of the Board
Yossi Hatan Vice President - Finance
Gilad Rosenberg Vice President Clinical Development
Tamar Kfir Director
Ofir Shachaf Director
Search macroaxis.com